MENU

MS & Immune Disorders

The Latest
More in MS & Immune Disorders

News

05.28.20

FDA Removes Category C Warning of Possible Risk in Pregnancy and Breast Feeding for MS Treatment Interferon Beta-1a 
  • KEYWORDS:
  • Interferon beta
  • Multiple sclerosis
  • Pregnancy
  • Relapsing Multiple Sclerosis

News

05.24.20

T-Cell Immunotherapy for Progressive MS Shows Safety and Efficacy
  • KEYWORDS:
  • Multiple sclerosis
  • Secondary progressive multiple sclerosis

News

05.23.20

Continued Safety and Tolerability of Satralizumab for NMOSD
  • KEYWORDS:
  • neuromyelitis optica spectrum disorder
  • NMOSD
  • Satralizumab

News

05.23.20

Evobrutinib Treatment Reduced Annualized Relapse Rate Sustained in Open-Label Extension Study
  • KEYWORDS:
  • Evobrutinib
  • Meeting coverage
  • Multiple sclerosis
  • Relapsing Multiple Sclerosis

News

05.07.20

New Social Networking Platform for the Multiple Sclerosis Community
  • KEYWORDS:
  • Multiple sclerosis
  • Relapsing Multiple Sclerosis
Neuroschistosomiasis image

Case Report

Neuroschistosomiasis

Complete neurologic recovery after acute cauda equina syndrome

Paul M. Elsbernd, MD; Kathryn J. Lago, DO; Tatjana P. Calvano, DO; and John H. Sladky, MD

April 2020 teaser

Cover Focus

Giant Cell Arteritis

Headache occurs in 70% to 80% of people with giant cell arteritis.

Britany Klenofsky, MD, and Huma U. Sheikh, MD

Diagnosing Secondary Headaches image

Cover Focus

Diagnosing Secondary Headaches

The SNOOP10 mnemonic is a useful framework for diagnosing secondary headaches.

Chia-Chun Chiang, MD, and Juliana VanderPluym, MD, FRCP, FAHS

April 2020 teaser

Guest Medical Editor's Page

Secondary Headaches

A guide to navigating the waters of headache evaluation.

Rashmi B. Halker Singh, MD, FAHS, FAAN

News

04.28.20

Data Show Ocrelizumab Reduces Disability Progression and Disease Risk in MS 
  • KEYWORDS:
  • Multiple sclerosis
  • Ocrelizumab
  • Relapsing Multiple Sclerosis

News

04.22.20

First Participant Received Batoclimab in Phase 1b/2a Trial for Neuromyelitis Optica Spectrum Disorder
  • KEYWORDS:
  • batoclimab
  • Neuroimmune disorders
  • neuromyelitis optica spectrum disorder
  • Neuromyelitis optica spectrum disorders

News

04.20.20

Regulatory Agencies Consider 2-Hour Infusion Times for Ocrelizumab 
  • KEYWORDS:
  • Multiple sclerosis
  • Ocrelizumab
  • Relapsing Multiple Sclerosis

News

04.03.20

Interferons for Multiple Sclerosis No Longer Labeled as Contraindicated During Pregnancy and Breastfeeding
  • KEYWORDS:
  • Interferon beta
  • Multiple sclerosis
  • Pregnancy
  • Relapsing Multiple Sclerosis

News

03.26.20

FDA Approves Ozanimod for Relapsing Multiple Sclerosis 
  • KEYWORDS:
  • FDA Approvals
  • Multiple sclerosis
  • Ozanimod
  • Relapsing Multiple Sclerosis

News

03.19.20

New Drug Application for Ponesimod Was Submitted to FDA
  • KEYWORDS:
  • Multiple sclerosis
  • Ponesimod
  • Relapsing Multiple Sclerosis
  • Teriflunomide
Multiple Sclerosis Minute: Natalizumab Extended-Interval Dosing image

Columns

Multiple Sclerosis Minute: Natalizumab Extended-Interval Dosing

The extended interval dosing approach for natalizumab treatment reduces the risk of progressive multifocal leukoencephalopathy.

Lana Zhotvis Ryerson

Show More